TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30251088

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Ketogenic Diet (VLCKD)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 178
Study: 27840301

Group type: EXPERIMENTAL
Intervention: teriparatide 20‐mcg SC daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: denosumab 60‐mg SC every 6 months
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: combined teriparatide/denosumab
Number of subjects: 94
Study: 26222356

Group type: EXPERIMENTAL
Intervention: Combination of pharmacotherapy and lidocaine block (Group II)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No additional treatment (Group I)
Number of subjects: 13
Study: 24691140

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computed tomography (DCE-CT)
Number of subjects: 12
Study: 22540188

Group type: EXPERIMENTAL
Intervention: d4T/3TC-based cART
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Higher baseline BMI
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Lower baseline hemoglobin
Number of subjects: 650

Group type: COMPARATOR
Intervention: No lactic acidosis symptoms
Number of subjects: 650
Study: 19179298

Group type: EXPERIMENTAL
Intervention: synthetic salmon calcitonin (ssCT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: recombinant salmon calcitonin (rsCT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: ssCT and rsCT
Number of subjects: 36
Study: 17524724

Group type: EXPERIMENTAL
Intervention: Intervention applied to 13 randomly selected schools
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Food taken as a proxy measure
Number of subjects: 1168
Study: 16018807

Group type: EXPERIMENTAL
Intervention: VOCs analysis in NSCLC patients post-surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VOCs analysis in NSCLC patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: VOCs analysis in healthy smokers and non-smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: VOCs analysis in patients with COPD
Number of subjects: 0
Study: 15463829

Group type: EXPERIMENTAL
Intervention: Creon 10,000 Minimicrospheres
Number of subjects: 59

Group type: COMPARATOR
Intervention: Creon 8,000 microspheres
Number of subjects: 59
Study: 10527999

Group type: EXPERIMENTAL
Intervention: Genetic sonography (nuchal translucency measurement at 10‐14 weeks and second trimester targeted ultrasound including fetal echocardiography)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Genetic sonography
Number of subjects: 153
Study: 8824685

Group type: COMPARATOR
Intervention: Lacidipine-based treatment (SHELL trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lacidipine-based treatment (ELSA trial)
Number of subjects: 0
Study: 2252400

Group type: EXPERIMENTAL
Intervention: Massage (10 minute massage to the back)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (10 minute visit without massage)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 6783420

Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide infusion at 1 pmol kg‐1 min‐1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide infusion at 4 pmol kg‐1 min‐1
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no pancreatic polypeptide infusion)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide infusion
Number of subjects: 17
Study: 31200985

Group type: EXPERIMENTAL
Intervention: Project Planned Outreach, Intervention, Naloxone, and Treatment (POINT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 30665020

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships® (PFR) home visitation program
Number of subjects: 247

Group type: COMPARATOR
Intervention: Resource and referral control condition
Number of subjects: 247
Study: 29083222

Group type: EXPERIMENTAL
Intervention: Growing Pro‐Social (GPS) program
Number of subjects: 254

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 254
Study: 25295964

Group type: EXPERIMENTAL
Intervention: Internet-based learning module and small-group debriefing
Number of subjects: 499
Study: 23784600

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic aspirin use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle including appropriate diet
Number of subjects: 0
Study: 21635618

Group type: EXPERIMENTAL
Intervention: Autologous PRP injections
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 14
Study: 19543672

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg body weight twice daily)
Number of subjects: 40
Study: 17626054

Group type: EXPERIMENTAL
Intervention: Shock wave therapy (SWT)
Number of subjects: 948
Study: 12677620

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 2.5 mg and fentanyl 25 microgram with epinephrine 100 microgram (Group BFE)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group: Intrathecal bupivacaine 2.5 mg and fentanyl 25 microgram without epinephrine (Group BF)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group BFE
Number of subjects: 108

Group type: COMPARATOR
Intervention: Group BF
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 11153636

Group type: EXPERIMENTAL
Intervention: Ethics consultation offered
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ethics consultation not offered
Number of subjects: 74
Study: 9558774

Group type: EXPERIMENTAL
Intervention: Rifaximin (600 mg/day x 3/day), Amoxicillin (1 g x 2/day), Omeprazole (40 mg/day) for 2 weeks (protocol A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Rifaximin (600 mg/day x 3/day), Erythromycin‐ethylsuccinate (600 mg x 3/day), Omeprazole (40 mg/day) for 2 weeks (protocol B)
Number of subjects: 23
Study: 1531926

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 3 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 4020412

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin (Adriamycin)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonrandomized control group
Number of subjects: 90
Study: 31027480

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of remifentanil
Number of subjects: 34

Group type: COMPARATOR
Intervention: Abrupt discontinuation of remifentanil
Number of subjects: 34
Study: 30554184

Group type: EXPERIMENTAL
Intervention: Topical vancomycin treatment group (257 patients)
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: Topical vancomycin treatment group
Number of subjects: 2632
Study: 27355810

Group type: EXPERIMENTAL
Intervention: Medicaid patients
Number of subjects: 600000

Group type: COMPARATOR
Intervention: Privately insured patients
Number of subjects: 600000

Group type: EXPERIMENTAL
Intervention: Medicaid appointments with nonphysician providers
Number of subjects: 600000

Group type: COMPARATOR
Intervention: Private insurance appointments with nonphysician providers
Number of subjects: 600000

Group type: EXPERIMENTAL
Intervention: Wait times for new Medicaid patients
Number of subjects: 600000

Group type: COMPARATOR
Intervention: Wait times for new privately insured patients
Number of subjects: 600000
Study: 25373012

Group type: EXPERIMENTAL
Intervention: Combination inositol and glucomannan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inositol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glucomannan
Number of subjects: 40
Study: 22114108

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination and controlled ovarian stimulation (IUI‐COS)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 253
Study: 19885850

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (200 mL PJ/day) for 3 days before surgery
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Walnuts (35 g walnuts/day) for 3 days before surgery
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study: 19253503

Group type: EXPERIMENTAL
Intervention: 10% Dextran-40 in NSS
Number of subjects: 104

Group type: COMPARATOR
Intervention: 10% Haes-steril in NSS
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 104
Study: 15564311

Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 255

Group type: COMPARATOR
Intervention: appropriate care without hylan G-F 20
Number of subjects: 255
Study: 12618280

Group type: EXPERIMENTAL
Intervention: Saturated Fatty Acids (SFA diet)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Monounsaturated Fatty Acids (MUFA diet)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.6 g/day)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids supplementation
Number of subjects: 162
Study: 10546927

Group type: EXPERIMENTAL
Intervention: Meloxicam, 15 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin (positive control)
Number of subjects: 0
Study: 8668411

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous (IV) rehydration treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral rehydration solutions (ORSs) of different sodium content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient settings
Number of subjects: 0
Study: 1853156

Group type: EXPERIMENTAL
Intervention: 4-gram 5-aminosalicylic acid retention enema (Mesasal) administered for seven consecutive nights and one additional enema on the eighth night
Number of subjects: 10
Study: 6882699

Group type: EXPERIMENTAL
Intervention: New tricyclic antidepressant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hostility
Number of subjects: 0
Study: 31229990

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 24 months
Number of subjects: 228

Group type: COMPARATOR
Intervention: Famotidine 40 mg daily for 24 months
Number of subjects: 228
Study: 29445178

Group type: EXPERIMENTAL
Intervention: Clostridium butyricum (CB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 27792396

Group type: EXPERIMENTAL
Intervention: DHA (1,500 mg/day of DHA-enriched oil)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (1,500 mg/day of sunflower oil)
Number of subjects: 57
Study: 24694667

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Combined SES and EES
Number of subjects: 754

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 754
Study: 22853818

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (AS) 2 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (AS) 4 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (AS) 8 mg/kg
Number of subjects: 24
Study: 20159049

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius CECT5713 (2 x 10(8) CFU daily for 4 weeks)
Number of subjects: 40
Study: 17934817

Group type: EXPERIMENTAL
Intervention: PHQ-9
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: BDI-II
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: CES-D
Number of subjects: 129
Study: 15740629

Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-smoking
Number of subjects: 16
Study: 12232452

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg/dose, subcutaneous, twice daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Unfractionated heparin (adjusted dose, intravenous)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 59
Study: 10424385

Group type: EXPERIMENTAL
Intervention: Inhalation of mercury vapour (0.6-10 microg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Inhalation of pure air
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inhalation of mercury vapour
Number of subjects: 39
Study: 7547611

Group type: EXPERIMENTAL
Intervention: Sorting cards into two piles whilst saying the colour of the card aloud
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reading aloud
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sorting cards quietly into one, two, four, 13 and 26 piles
Number of subjects: 16
Study: 2188766

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7386840

Group type: EXPERIMENTAL
Intervention: Minaxolone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Minaxolone with fentanyl
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Minaxolone without fentanyl)
Number of subjects: 100
Study: 31630567

Group type: EXPERIMENTAL
Intervention: Response adaptive randomization with maintained control allocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response adaptive randomization with increased control allocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response adaptive randomization with variable control allocation
Number of subjects: 0
Study: 31108818

Group type: EXPERIMENTAL
Intervention: Triangular WL 'High in/Alto em' (Alto)
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: Triangular WL 'A lot of/Muito' (Muito)
Number of subjects: 2419

Group type: COMPARATOR
Intervention: Control condition (no WL)
Number of subjects: 2419
Study: 28880260

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 932

Group type: COMPARATOR
Intervention: Open-label steroid therapy
Number of subjects: 932
Study: 26341755

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo/SOC
Number of subjects: 159
Study: 22831916

Group type: EXPERIMENTAL
Intervention: 3-month physical activity behavior change intervention (supervised aerobic exercise of 150 weekly minutes at moderate intensity and resistance exercise 2 sessions per week)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3-month physical activity behavior change intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: usual care group (UCG)
Number of subjects: 28
Study: 21407090

Group type: EXPERIMENTAL
Intervention: Transparent dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gauze dressings
Number of subjects: 0
Study: 19884576

Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNbeta) in patients with preserved bioactivity (n = 8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNbeta) in patients with lost bioactivity (n = 7)
Number of subjects: 15
Study: 17710587

Group type: EXPERIMENTAL
Intervention: 15 g/day pressurized whey protein
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 g/day pressurized whey protein
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 45 g/day pressurized whey protein
Number of subjects: 36
Study: 15296210

Group type: EXPERIMENTAL
Intervention: Commonly used foot orthosis materials
Number of subjects: 10
Study: 11525226

Group type: EXPERIMENTAL
Intervention: Cervitec varnish containing 1% chlorhexidine (CHx) applied at baseline, 3-4 months, and 6 months.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group received prophylaxis using cotton pellet in water.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cervitec varnish containing 1% chlorhexidine (CHx).
Number of subjects: 200
Study: 11076449

Group type: EXPERIMENTAL
Intervention: Functional relaxation technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo-relaxation technique (control)
Number of subjects: 12
Study: 9228724

Group type: EXPERIMENTAL
Intervention: Alkali citrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High fluid intake and sensible diet
Number of subjects: 0
Study: 1326318

Group type: EXPERIMENTAL
Intervention: 1 mg/m2 body surface ACTH4-9 analog before and after each cisplatin cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3904337

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 30882166

Group type: EXPERIMENTAL
Intervention: Warm solution (37 degrees)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold fluid (20 degrees)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Room temperature fluid (24 degrees)
Number of subjects: 60
Study: 30058112

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg/day
Number of subjects: 2186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2186
Study: 27098452

Group type: EXPERIMENTAL
Intervention: Textured insole (n=88)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Smooth control insole (n=88)
Number of subjects: 176
Study: 25216464

Group type: EXPERIMENTAL
Intervention: Stepped Care Program (SCP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 240
Study: 22646082

Group type: EXPERIMENTAL
Intervention: ABA-based therapy sessions (2-3 sessions per week for 1 year)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (matched children with AS)
Number of subjects: 4
Study: 19864941

Group type: EXPERIMENTAL
Intervention: Leukocyte-containing, buffy-coat-depleted red blood cells
Number of subjects: 346

Group type: COMPARATOR
Intervention: Leukocyte-depleted red blood cells
Number of subjects: 346
Study: 17571741

Group type: EXPERIMENTAL
Intervention: Yogic practices (specifics on dosage and duration not available)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yogic practices
Number of subjects: 0
Study: 15661814

Group type: EXPERIMENTAL
Intervention: Evening samples (after activation with specific TLR ligands)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Post-exercise samples (after activation with specific TLR ligands)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Rest samples (before exercise)
Number of subjects: 19
Study: 11953038

Group type: EXPERIMENTAL
Intervention: CMV-specific T cell therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10440303

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention for up to 5 months at home
Number of subjects: 185

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 185
Study: 7757046

Group type: EXPERIMENTAL
Intervention: Operant treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Operant-cognitive treatment (OC)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Operant-respondent treatment (OR)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 71
Study: 2148326

Group type: EXPERIMENTAL
Intervention: dextroamphetamine (d‐AMPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: desipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: desipramine‐alprazolam combination
Number of subjects: 0
Study: 31970830

Group type: EXPERIMENTAL
Intervention: Hospital-family holistic care model based on 'Timing It Right'
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (routine care and follow-up)
Number of subjects: 119
Study: 30932653

Group type: EXPERIMENTAL
Intervention: Kerr beam self-cleaning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct and inverse cascade towards high mode numbers
Number of subjects: 0
Study: 27866347

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with heating sheet (HRT group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance training (RT group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Heating sheet only (HEAT group)
Number of subjects: 21
Study: 25562579

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (cognitive-behavioral therapy and/or pharmacotherapy)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1004
Study: 23995765

Group type: EXPERIMENTAL
Intervention: Changes in joint space width (JSW) over 3 years
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Changes in WOMAC score over 3 years
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: JSW and WOMAC score changes included in the same model
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Knee replacement occurrence
Number of subjects: 133
Study: 22409097

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control condition (no CBT)
Number of subjects: 100
Study: 19133917

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 2184
Study: 17045352

Group type: EXPERIMENTAL
Intervention: LDL-A (new equation using total cholesterol and triglycerides)
Number of subjects: 230

Group type: COMPARATOR
Intervention: LDL-F (Friedewald formula)
Number of subjects: 230
Study: 15325679

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Step II diet
Number of subjects: 59
Study: 11554424

Group type: EXPERIMENTAL
Intervention: Nicardipine HCl oral sustained-release dosage form
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cardene SR
Number of subjects: 6
Study: 9456565

Group type: EXPERIMENTAL
Intervention: no‐RROP
Number of subjects: 100

Group type: COMPARATOR
Intervention: RROP
Number of subjects: 100
Study: 8166894

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including bupivacaine, prilocaine, and control)
Number of subjects: 0
Study: 2459516

Group type: EXPERIMENTAL
Intervention: Ketanserin (up to a dose of 10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of phentolamine and ritanserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0
Study: 30185106

Group type: EXPERIMENTAL
Intervention: Position on mother's abdomen (Group AL)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Position 20 cm below the introitus (Group BL)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 199